For additional resources on VeriStrat, please download the PDFs below.
Using VeriStrat to help you guide treatment decisions
VeriStrat is intended for 2nd and 3rd line advanced non-small cell lung cancer(NSCLC) patients who are eligible for EGFR-TKI therapy. VeriStrat provides a clear test result, VeriStrat Good or VeriStrat Poor, that correlates with survival outcomes after EGFR-TKI therapy.1
Since VeriStrat is a non-invasive, pre-treatment serum test that does not require a tissue biopsy, all 2nd and 3rd line advanced NSCLC patients that can provide a blood sample are eligible for VeriStrat testing. Results are typically returned to you in less than 72 hours. This information, along with other clinical factors, helps you personalize therapy and possibly improve patient outcomes.
*VeriStrat test results should be used in combination with the patient’s clinical history, other diagnostic tests, and clinicopathological factors, customarily evaluated by a qualified physician.
References
1.Taguchi F, Solomon B, Gregorc V, et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst. 2007;99:838-846.
2. NCCN Clinical Practice Guidelines in Oncology™: Non-Small Cell Lung Cancer, v.1,2010. Available at: http://www.nccn.org
